PAHALGAM DIALOGUES ON CANCER
Saturday, 19 August 2023, Pahalgam, Kashmir
We would like to extend an invitation for your participation in this premier practice-transforming programme as well as an industry and government policy forum designed to gather stakeholders and key opinion leaders in the field. The event will showcase a range of experts, including Medical, Radiation, and Surgical and Surgical Robotics oncologists, as well as leaders from the oncology biotechnology and pharmaceutical industries, molecular diagnostic professionals, policy planners from the Health and Pharmaceutical Ministries, representatives from health media outlets, and key health investment professionals.
At “Pahalgam Dialogues on Cancer” (pDOC) , we aim to provide a dynamic platform for productive discussions in oncology around a wide range of topics, including blood biopsies, actionable mutations, immunotherapy, targeted therapies, proton beam, augmented reality, and 5G-enabled surgery.The conference seeks to generate constructive input on practical preventive strategies, improved access to standardised treatment, and management controversies while ensuring the dissemination of clear take-home messages. The conference will span the entire day, with each session providing participants the opportunity to interact with leading experts in the field through short lectures and case-based panel discussions. Your esteemed presence holds immense significance in our collective mission of raising awareness and seeking meaningful preventive strategies towards delivering timely, homogenous diagnosis and cancer treatment to Indian populations and those from other countries seeking the same here increasingly now.
We hope that you will join us to share your insights and expertise, interact with related industry captains and train your management cadres.Kindly confirm your participation at your earliest convenience, as your involvement will be instrumental in shaping this remarkable conference.
CHAIRMAN's MESSAGE
In the run up to ‘Universal Health Coverage’ we would be naive to ignore major obstacles posed by Global inequalities, dynamic Cancer demographics, and upsurge of translational research. I feel these are formidable challenges at worst not impossible to overcome.
Provided we reaffirm our commitment to achieve our goal from time to time, ponder over and embrace nouvelle strategies to drive ‘value’ into this great game. Is why I implore all eminent stake holders in ‘transitioning countries’ like ours to join Us at pDOC.
The valley of shepherd’s lovingly offers its pristine environs as the stage for this academic feast.
Come Ye friends! Participate and Partake.
I wish you happy brainstorming.
PROVISIONAL AGENDA
Radioimmunoconjugates in Cancer Treatment – where, when, how?
Monoclonal antibodies in Cancer Treatment – is this a path worth taking?
A Flexible Future : Transforming the paradigm of HER2 +ve Breast Cancer treatment
Management of HER 2 -ve metastatic breast cancer
SBRT, IORT, ZAPX & beyond
Check point inhibitors – saviours for cancer patients
Optimising treatment strategies in management of 1L mNSCLC
Blood Biopsies should replace tissue diagnosis – is it time already?
Minimal Residual Disease Detection for Solid Tumors – Current Evidence
Robotics and its evolution – can be ignored no more
PIPAC / HIPEC – remarkable drug delivery systems
PROVISIONAL AGENDA
Radioimmunoconjugates in Cancer Treatment – where, when, how?
Monoclonal antibodies in Cancer Treatment – is this a path worth taking?
A Flexible Future : Transforming the paradigm of HER2 +ve Breast Cancer treatment
Management of HER 2 -ve metastatic breast cancer?
SBRT, IORT, ZAPX & beyond
Defining Treatment Landscape in Hodgkin’s Lymphoma with Adcetris
Check point inhibitors – saviours for cancer patients
Optimising treatment strategies in management of 1L mNSCLC
Blood Biopsies should replace tissue diagnosis – is it time already?
Minimal Residual Disease Detection for Solid Tumors – Current Evidence
Robotics and its evolution – can be ignored no more
PIPAC / HIPEC – remarkable drug delivery systems
Strategies – to incorporate expensive cancer treatments in India’s public health system
PROVISIONAL AGENDA
Radioimmunoconjugates in Cancer Treatment – where, when, how?
Monoclonal antibodies in Cancer Treatment – is this a path worth taking?
A Flexible Future : Transforming the paradigm of HER2 +ve Breast Cancer treatment
Management of HER 2 -ve metastatic breast cancer
SBRT, IORT, ZAPX & beyond
Defining Treatment Landscape in Hodgkin’s Lymphoma with Adcetris
Check point inhibitors – saviours for cancer patients
Optimising treatment strategies in management of 1L mNSCLC
Blood Biopsies should replace tissue diagnosis – is it time already?
Minimal Residual Disease Detection for Solid Tumors – Current Evidence
Robotics and its evolution – can be ignored no more
PIPAC / HIPEC – remarkable drug delivery systems
Strategies – to incorporate expensive cancer treatments in India’s public health system
Dr Abdul Rashid Lone
Dr Ajay Bapna
Dr Anusheel Munshi
Dr Aparna Dhar
Dr Ashwin K R
OUR
EMINENT
FACULTY
EMINENT
Dr Ashok Kumar
Dr Ashutosh Gupta
Dr D Raghunadha Rao
Dr Darshana Patil
Dr Deepak Abrol
Dr Feroz Pasha
Dr G K Jadhav
Prof (Dr)Gaurav Aggarwal
Dr G K Rath
Dr Girish Telang
Mr Gopal Agrawal
Mr Hideshi Yamamoto
Dr Javvid Muzzamil
Dr Jyoti Bajpai
Dr K Govind Babu
Dr Manish Singhal
Dr Maqbool Lone
Dr. Mir Mohd. Hussain
Dr P K Das
Dr R Rajkumar
Dr Rajeev Bedi
Prof Rakesh Jalali
Dr Reena Nayyar
Dr Rohit V Nayyar
Dr Ruqaiya Mir
Dr S H Advani
Dr Sachin Almel
Dr Sajad Qazi
Dr Sameer Kaul
Dr Shabnam Bashir
Dr Sheikh Aijaz Aziz
Dr Shekhar Salkar
Dr Soma Shekhar
Dr Sudhir Gupta
DR. (PROF) S K RAWAL
Dr Syed Nissar
Dr Thomas Varughese
Dr Ullas Batra
Dr (Prof) U S Vishal Rao
Dr Vashishth Maniar
Dr Vinay Deshmane
Dr Vineet Talwar
Dr Vinod Raina
Dr Vivek Tandon
OUR
EMINENT
FACULTY
EMINENT
Dr Abdul Rashid Lone
Dr Ajay Bapna
Dr Anusheel Munshi
Dr Aparna Dhar
Dr Ashwin K R
Dr Ashok Kumar
Dr Ashutosh Gupta
Dr D Raghunadha Rao
Dr Darshana Patil
Dr Deepak Abrol
Dr Feroz Pasha
Dr G K Jadhav
Prof (Dr)Gaurav Aggarwal
Dr G K Rath
Dr Girish Telang
Mr Gopal Agrawal
Mr Hideshi Yamamoto
Dr Javvid Muzzamil
Dr Jyoti Bajpai
Dr K Govind Babu
Dr Manish Singhal
Dr Maqbool Lone
Dr. Mir Mohd. Hussain
Dr P K Das
Dr R Rajkumar
Dr Rajeev Bedi
Prof Rakesh Jalali
Dr Reena Nayyar
Dr Rohit V Nayyar
Dr Ruqaiya Mir
Dr S H Advani
Dr Sachin Almel
Dr Sajad Qazi
Dr Sameer Kaul
Dr Shabnam Bashir
Dr Sheikh Aijaz Aziz
Dr Shekhar Salkar
Dr Soma Shekhar
Dr Sudhir Gupta
DR. (PROF) S K RAWAL
Dr Syed Nissar
Dr Thomas Varughese
Dr Ullas Batra
Dr (Prof) U S Vishal Rao
Dr Vashishth Maniar
Dr Vinay Deshmane
Dr Vineet Talwar
Dr Vinod Raina
Dr Vivek Tandon
EXHIBITION HALL
EXHIBITION HALL
SUPPORTERS
ORGANISING TEAM
Dr. Sameer Kaul
Organizing Chairman
Pahalgam Dialogues on Cancer
bcpbf-THE CANCER FOUNDATION
Dr. Feroz Pasha
Organizing Secretary
Pahalgam Dialogues on Cancer
bcpbf-THE CANCER FOUNDATION
Mridul Arora
Organizing Secretary
Pahalgam Dialogues on Cancer
bcpbf-THE CANCER FOUNDATION
Naveen Ahuja
Organizing Member
Pahalgam Dialogues on Cancer
bcpbf-THE CANCER FOUNDATION
Dr. Shahin Nooreyezdan
Organizing Member
Pahalgam Dialogues on Cancer
Apollo Hospitals, New Delhi
Prof. Rakesh Jalali
Organizing Member
Pahalgam Dialogues on Cancer
Apollo Proton Cancer Centre, Chennai
Dr. G K Jadhav
Organizing Member
Pahalgam Dialogues on Cancer
Apollo Cancer Institute, New Delhi
Dr. P K Das
Organizing Member
Pahalgam Dialogues on Cancer
Apollo Cancer Institute, New Delhi
32108+
People Screened
780+
Financially Assisted
276+
Provided Free Medicine
32108+
780+
276+
People Screened
Financially Assisted
Provided Free Medicine
CERTIFICATIONS
bcpbf-THE CANCER FOUNDATION (BCPBF) is registered under the Societies Registration Act (XXI) 1860, Govt. of NCT of Delhi. Indian donations shall be exempted from Income tax under 80G of Income Tax Act 1961 as applicable.
bcpbf-THE CANCER FOUNDATION (BCPBF) is registered no (231661601) under the Foreign Contribution (Regulation) Act 2010, Govt. of India.